TVGN-920 / Tevogen - LARVOL DELTA

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920 (GlobeNewswire) - "Using Microsoft’s suite of advanced tools, Tevogen Bio is proactively investigating potential treatments for HPV to create a portfolio of oncology products. The company has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T cell (CTL) targets to choose for a clinical trial for TVGN 920, its first oncology product. Through Tevogen’s proprietary ExacTcell technology, where CTLs are trained to detect specific targets and then expanded, the company aims to be prepared to deliver an HPV-specific CTL treatment."

Commercial • Oncology

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow (GlobeNewswire) - "Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment...'With compelling evidence that SARS-CoV-2 remains a serious threat to those undergoing immunosuppressive treatments and chemotherapy, our first pivotal study with TVGN 489 is being designed specifically to help these vulnerable patients combat the infection.'....Pipeline: TVGN 920: Cervical cancer prevention; TVGN 930: EBV-associated lymphomas; TVGN 960: Mouth and throat cancer; TVGN 601: Multiple sclerosis."

Commercial • Cervical Cancer • Gynecologic Cancers • Head and Neck Cancer • Hematological Malignancies • Immunology • Lymphoma • Multiple Sclerosis • Novel Coronavirus Disease • Oncology • Oral Cancer • Solid Tumor